Benzinga | Oct 21, 2020 09:03AM EDT

Pulmatrix Announces Commercial Launch Of FEND OTC Nasal Hygiene Product Proven to Reduce Airborne Respiratory Droplets, With Partner Sensory Cloud

LEXINGTON, Mass., Oct. 21, 2020 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ:PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies for serious pulmonary and non-pulmonary disease using its patented iSPERSE(tm) technology, today announced marketing and distribution partner Sensory Cloud's commercial launch of FEND, a hypertonic calcium chloride salt solution with nasal mister. FEND is a potentially important new hygiene option beyond masks to combat the ongoing COVD-19 pandemic. Pulmatrix licensed the rights to the Company's NasoCalm proprietary formulations (PUR003 and PUR006) to Sensory Cloud, now integral to the product FEND, with Sensory Cloud to market and distribute FEND, and Pulmatrix to receive escalating royalties, upon commencement of sales. FEND is now available for purchase at www.hellofend.com.